Pliant Therapeutics, Inc. (PLRX) Stock Score, Valuation & Financial Research

Pliant Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for PLRX

Pliant Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.00. These figures are a research snapshot, not a buy or sell recommendation.

What Pliant Therapeutics, Inc. does

Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Pliant Therapeutics is a clinical-stage biopharmaceutical company that generates no product revenue. Its business model relies on raising capital through equity offerings and potential future milestone or royalty payments from strategic research and development collaborations to fund the discovery and development of integrin-based therapeutics.

Products and services

  • The company is developing a pipeline of small molecule integrin-based therapeutics, with lead programs including PLN-101095 for solid tumors and other candidates targeting fibrosis.

Customer types

Clinical trial sites and patients.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party vendors for clinical trial management, data collection, and the manufacturing of drug substance and drug product for clinical use. Specific supplier names are not disclosed. Source

Business strengths to evaluate

  • Proprietary INTEGRIS platform for integrin-based drug discovery Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on third-party manufacturers and clinical trial providers Source
  • Significant capital requirements to fund research and development Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

PLRX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.00
Market capitalization:
61.62M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -92.29M
Free cash flow:
USD -128.71M
Cash:
USD 24.88M
Total debt:
USD 28.74M
EPS:
USD -1.49

What stands out

  • Free cash flow is USD -128.71M, negative for the stored period.
  • The balance sheet shows USD 24.88M of cash versus USD 28.74M of total debt, with debt exceeding cash on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Debt exceeds cash by USD 3.86M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for PLRX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can PLRX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Does PLRX's balance between cash and debt leave enough flexibility if business conditions weaken?
  • What specifically needs to improve for PLRX to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of PLRX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-12.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research PLRX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.